NeuroPace, Inc. (NPCE)

Market Cap	622.99M +69.1%
Revenue (ttm)	99.99M +25.1%
Net Income	-21.47M
EPS	-0.66
Shares Out	33.95M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	329,113
Open	19.50
Previous Close	19.29
Day's Range	18.32 - 19.60
52-Week Range	7.56 - 19.60
Beta	1.93
Analysts	Strong Buy
Price Target	18.33 (-0.11%)
Earnings Date	May 12, 2026

About NPCE

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programmin...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Apr 22, 2021
• Employees: 209
• Stock Exchange: NASDAQ
• Ticker Symbol: NPCE
• Website: https://www.neuropace.com

Financial Performance

In 2025, NeuroPace's revenue was $99.99 million, an increase of 25.13% compared to the previous year's $79.91 million. Losses were -$21.47 million, -20.91% less than in 2024.

Analyst Summary

According to 6 analysts, the average rating for NPCE stock is "Strong Buy." The 12-month stock price target is $18.33, which is a decrease of -0.11% from the latest price.

Price Target

$18.33

(-0.11% downside)

Analyst Consensus: Strong Buy